Faculty of Medicine, Department of Clinical Sciences Lund, Orthopedics, Lund University, Lund 221 85, Sweden.
Biomedical Engineering, Glasgow University, Glasgow G12 8QQ, U.K.
ACS Biomater Sci Eng. 2020 May 11;6(5):2867-2878. doi: 10.1021/acsbiomaterials.9b01574. Epub 2020 Apr 6.
Fracture nonunions are common in orthopedics and their treatment often involves multiple surgical interventions. The aim of this study was to fabricate and characterize a gelatin-nano-hydroxyapatite membrane (GM)-based bone bandage for controlled delivery of bio-active molecules; recombinant human bone morphogenic protein-2 (rhBMP-2) and zoledronic acid (ZA) to promote osteoinduction and prevent callus resorption, respectively. In vitro cell-material interaction experiments using MC3T3 cells seeded on the GM indicated good biocompatibility. rhBMP-2-functionalized GM promoted osteogenic differentiation of MC3T3 cells and the rhBMP-2 bio-activity thus remained, as indicated by increased levels of alkaline phosphatase compared to only GM. The GM released a small amount (1.1%) of rhBMP-2 in vitro over a period of 5 weeks, demonstrating a strong interaction of rhBMP-2 with the GM. In the first animal study, the GM specimens loaded with rhBMP-2 or with the combination of rhBMP-2 + ZA were placed in the abdominal muscle pouch of rats. In the GM + rhBMP-2 + ZA group, significantly higher bone volume (21.5 ± 5.9 vs 2.7 ± 1.0 mm) and area (3.3 ± 2.3 vs 1.0 ± 0.4 mm) of bone were observed compared to GM + rhBMP-2 after 4 weeks, as indicated by micro-computed tomography and histomorphometry, respectively. Finally, a nonunion model in rats was used to evaluate the efficacy of the GM bandage and bio-active molecules in healing of fracture nonunions. The GM functionalized with rhBMP-2 + ZA led to higher bone formation around the fracture (63.9 ± 19.0 vs 31.8 ± 3.7 mm) and stronger fracture callus (110.8 ± 46.8 vs 45.6 ± 17.8 N) compared to the empty controls. However, the overall union rate was only marginally improved. The GM alone or combined with ZA did not aid in bone healing in this model. Thus, this study shows that controlled delivery of rhBMP-2 + ZA via the developed GM is a promising approach that could aid in earlier full load bearing in patients with nonunion.
骨折不愈合在骨科中很常见,其治疗通常涉及多次手术干预。本研究的目的是制备和表征一种明胶-纳米羟基磷灰石膜(GM)基骨绷带,用于控制生物活性分子的递送;重组人骨形态发生蛋白-2(rhBMP-2)和唑来膦酸(ZA)分别促进成骨诱导和防止骨痂吸收。使用接种在 GM 上的 MC3T3 细胞进行的体外细胞-材料相互作用实验表明其具有良好的生物相容性。rhBMP-2 功能化 GM 促进了 MC3T3 细胞的成骨分化,并且 rhBMP-2 的生物活性仍然存在,碱性磷酸酶水平的增加表明了这一点,与仅 GM 相比有所增加。GM 在体外 5 周内释放少量(1.1%)rhBMP-2,表明 rhBMP-2 与 GM 之间具有很强的相互作用。在第一项动物研究中,将负载 rhBMP-2 的 GM 标本或负载 rhBMP-2+ZA 的 GM 标本放置在大鼠的腹肌肉囊中。在 GM+rhBMP-2+ZA 组中,与 GM+rhBMP-2 相比,在 4 周后通过 micro-CT 和组织形态计量术分别观察到显著更高的骨体积(21.5±5.9 vs 2.7±1.0 mm)和面积(3.3±2.3 vs 1.0±0.4 mm)。最后,在大鼠非愈合模型中评估了 GM 绷带和生物活性分子在骨折不愈合愈合中的疗效。负载 rhBMP-2+ZA 的 GM 导致骨折周围有更高的骨形成(63.9±19.0 vs 31.8±3.7 mm)和更强的骨折痂(110.8±46.8 vs 45.6±17.8 N),与空对照相比。然而,整体愈合率仅略有提高。GM 单独或与 ZA 联合使用并不能促进该模型中的骨愈合。因此,本研究表明,通过开发的 GM 控制递送 rhBMP-2+ZA 是一种很有前途的方法,可以帮助非愈合患者更早地完全负重。